The development of vaccine strategies that expand cellular immune breadth will be crucial for achieving immunologic coverage of the enormous global genetic diversity of HIV-1 1,2 . Moreover, the breadth of Gag-specific cellular immune responses has been shown to correlate with control of HIV-1 replication in humans 4 and control of simian immunodeficiency virus (SIV) challenges in vaccinated rhesus monkeys 5 . Polyvalent mosaic proteins are assembled from natural sequences by in silico recombination and are optimized to provide maximal coverage of potential T cell epitopes (PTEs) for a given valency 3 . Mosaic antigens are full-length proteins that are designed to preserve natural antigen expression and processing. We used a bivalent mosaic strategy consisting of two HIV-1 Gag, Pol and Env antigens to balance the competing issues of theoretical coverage and practical utility. Here we report the breadth and magnitude of epitope-specific CD8 + and CD4 + T lymphocyte responses elicited by mosaic, consensus and natural sequence HIV-1 antigens in rhesus monkeys. We immunized 27 outbred rhesus monkeys with a single injection of recombinant adenovirus serotype 26 (rAd26) vectors 6 expressing the following antigens: bivalent mosaic (n = 7), M consensus 7 (n = 7), bivalent combined clade B + clade C (n = 7) or optimal natural clade C (n = 6) HIV-1 Gag, Pol and Env antigens. We administered a total dose of 3 × 10 10 viral particles of rAd26 vectors expressing these antigens once intramuscularly (i.m.) to each monkey. The optimal clade C antigens were the natural strain sequences selected to provide maximal PTE coverage of clade C sequences (Methods). We assessed the breadth and magnitude of vaccine-elicited HIV-1-specific T lymphocyte responses by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assays at week 4 after immunization using pools and subpools of peptides that included all global PTEs found in at least 15% of HIV-1 M group sequences 8 . We resolved all individual peptide responses and performed cell-depleted IFN-γ ELISPOT assays to determine whether the reactive peptides represented CD8 + or CD4 + T lymphocyte epitopes.
The worldwide diversity of HIV-1 presents an unprecedented challenge for vaccine development 1 The development of vaccine strategies that expand cellular immune breadth will be crucial for achieving immunologic coverage of the enormous global genetic diversity of HIV-1 1, 2 . Moreover, the breadth of Gag-specific cellular immune responses has been shown to correlate with control of HIV-1 replication in humans 4 and control of simian immunodeficiency virus (SIV) challenges in vaccinated rhesus monkeys 5 . Polyvalent mosaic proteins are assembled from natural sequences by in silico recombination and are optimized to provide maximal coverage of potential T cell epitopes (PTEs) for a given valency 3 . Mosaic antigens are full-length proteins that are designed to preserve natural antigen expression and processing. We used a bivalent mosaic strategy consisting of two HIV-1 Gag, Pol and Env antigens to balance the competing issues of theoretical coverage and practical utility. Here we report the breadth and magnitude of epitope-specific CD8 + and CD4 + T lymphocyte responses elicited by mosaic, consensus and natural sequence HIV-1 antigens in rhesus monkeys.
We immunized 27 outbred rhesus monkeys with a single injection of recombinant adenovirus serotype 26 (rAd26) vectors 6 expressing the following antigens: bivalent mosaic (n = 7), M consensus 7 (n = 7), bivalent combined clade B + clade C (n = 7) or optimal natural clade C (n = 6) HIV-1 Gag, Pol and Env antigens. We administered a total dose of 3 × 10 10 viral particles of rAd26 vectors expressing these antigens once intramuscularly (i.m.) to each monkey. The optimal clade C antigens were the natural strain sequences selected to provide maximal PTE coverage of clade C sequences (Methods). We assessed the breadth and magnitude of vaccine-elicited HIV-1-specific T lymphocyte responses by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assays at week 4 after immunization using pools and subpools of peptides that included all global PTEs found in at least 15% of HIV-1 M group sequences 8 . We resolved all individual peptide responses and performed cell-depleted IFN-γ ELISPOT assays to determine whether the reactive peptides represented CD8 + or CD4 + T lymphocyte epitopes.
The total number of Gag-, Pol-and Env-specific cellular immune responses to PTE peptides elicited by the mosaic antigens was 3.8-fold higher than the number of responses induced by the consensus or natural sequence antigens ( Fig. 1a ; P = 1 × 10 −11 , comparing the mosaic with the consensus antigens, the next highest group, on the basis of a Poisson regression model 9 ; http://cran.rproject.org/web/packages/lme4/ and http://www.R-project.org/). There were 4.4-fold more CD8 + than CD4 + T lymphocyte responses (P < 10 −11 ) and fewer responses to Env than to Gag or Pol ( Fig. 1a ; P < 0.0007). The median number of CD8 + T lymphocyte responses was highest for the mosaic vaccine, followed by the consensus, the combined B + C and the natural clade C vaccines ( Fig. 1a ; medians of 16, 5, 3 and 2 responses per monkey in each group, respectively). Although there were fewer CD4 + T lymphocyte responses overall, the same relative pattern emerged with the highest number of CD4 + T lymphocyte responses to the mosaic vaccine, followed by the consensus, the combined B + C and the natural clade C vaccines ( Fig. 1a 8 , and thus PTE peptide responses encompass both the recognition of a particular epitope (breadth) and the cross-recognition of variants of that epitope (depth). We performed a conservative analysis of breadth by assessing the number of reactive epitopic regions per monkey in which all reactive PTE peptides that overlapped by eight or more amino acids were counted as one event. In this conservative analysis, we observed that the mosaic antigens elicited 3.1-fold higher numbers of Gag-, Pol-and Env-specific epitopic regions as compared with the consensus antigens or natural sequence antigens ( Fig. 1b ; P = 1.6 × 10 −7 , Poisson regression). The median number of CD8 + T lymphocyte epitopic regions was higher for the mosaic vaccine (median of 8 response regions, range 7-14) than the other vaccines (median of 2 response regions, range 0-6). Epitopes showed some clustering across monkeys, as evidenced by regions of high epitope density (Supplementary Figs. 1 and 2) . Complete alignments of all responses are also available (Supplementary Fig. 3 ).
These data show that the mosaic antigens substantially increased cellular immune breadth as compared with the consensus or the natural sequence antigens. In addition to evaluating breadth, we also assessed the magnitude of all individual CD8 + and CD4 + T lymphocyte responses. The magnitude of these responses proved comparable among all groups ( Fig. 1c ; P = 0.58 and P = 0.99, respectively, two-sided Kolmogorov-Smirnov tests), demonstrating that the mosaic antigens expanded cellular immune breadth without compromising the magnitude of individual epitope-specific responses.
We next characterized the depth of the cellular immune responses elicited by the various vaccine regimens. We defined depth as the number of simultaneously elicited variant PTE peptides for a particular epitopic region. Inducing responses to multiple epitope variants may increase immunologic coverage of infecting virus sequences and may also block common escape routes in vivo or force the virus down suboptimal escape routes that incur high fitness costs 3 . The consensus and natural sequence antigens elicited responses that were characterized by a high degree of sequence identity between the vaccine sequences and the reactive PTE peptides, as exemplified by the responses in monkey 366 ( Fig. 2a and Supplementary Fig. 3 ). In contrast, the mosaic antigens elicited responses that were characterized by multiple reactive PTE peptides in particular epitopic regions. These peptides represented common variants and typically reflected the polymorphisms contained in the mosaic vaccine sequences, as exemplified by the responses in monkey 361 ( Fig. 2b and Supplementary  Fig. 3 ). A summary analysis shows that the mosaic antigens elicited a higher frequency of cellular immune responses to peptides with two or more targeted variants as compared with the consensus or natural sequence antigens ( Fig. 2c ; P = 0.001, Wilcoxon rank-sum test comparing the mosaic with the other groups).
To complement the analysis with PTE peptides, we also assessed the breadth of cellular immune responses in the vaccinated monkeys using overlapping peptides covering five HIV-1 Gag sequences: clade C DU422, clade C ZM651, consensus C, consensus A and consensus B. We determined cellular immune breadth by assessing reactivity to subpools of ten overlapping peptides spanning each Gag sequence. The mosaic antigens elicited a greater breadth of T lymphocyte responses as compared with the consensus or natural sequence antigens against all five Gag sequences ( Fig. 3 ; P = 1 × 10 −7 , binomial regression). In particular, the mosaic antigens proved superior to the optimal natural clade C antigens for inducing responses against clade C Gag (Fig. 3) . The mosaic antigens also elicited comparable responses to Gag from multiple clades, whereas the natural clade C antigens showed diminished responses to clade A Gag and clade B Gag. The breadth of Gag-specific responses elicited by the consensus, the combined B + C and the natural clade C vaccines were not statistically distinguishable, consistent with the results with PTE peptides (Fig. 1) .
To assess the durability of these observations, we boosted the monkeys that received the mosaic, consensus and optimal natural clade C antigens at week 40 with a total dose of 3 × 10 10 viral particles of the heterologous vector rAd5HVR48 (ref. 10) expressing HIV-1 Gag, Pol and Env antigens that matched the initial immunization sequences. We determined cellular immune breadth by assessing reactivity to subpools of ten PTE peptides at week 4 after the prime and at week 44 after the boost. The majority of CD8 + and CD4 + T lymphocyte responses that we observed after the priming immunization expanded after the boost, although we also detected new responses (Fig. 4a) . At week 44, the frequency of high-magnitude, epitopespecific cellular immune responses was comparable among groups (Fig. 4a) , but the number of subpool responses elicited by the mosaic antigens (median 27 responses per monkey) remained substantially higher than the number induced by the consensus antigens (median 11 responses per monkey) or the optimal natural clade C antigens (median 10 responses per monkey) ( Fig. 4b ; P < 0.001, Wilcoxon rank-sum tests for all pair-wise comparisons).
We also measured Env-specific humoral immune responses after the boost immunization by ELISAs (Fig. 4c) and luciferase-based pseudovirus neutralization assays 11 (Fig. 4d) . All groups showed comparable ELISA titers to clade C gp140 and comparable neutralizing antibody (NAb) responses to the tier 1 clade C virus MW965.26 (Fig. 4d) A   335  311  128  263  287  431  414  335  311  128  263  287  431  414  335  311  128  263  287  431  414  335  311  128  263  287  431  414  335  311  128  263  287  431  414   366  364  368  365  363  367  366  364  368  365  363  367  366  364  368  365  363  367  366  364  368  365  363  367  366  364  368  365 tier 1 clade B virus SF162.LS as compared with the consensus or natural clade C antigens ( Fig. 4d ; P = 0.02, Wilcoxon rank-sum test). NAb responses to the tier 1 clade A virus DJ263.8 were low in all groups (Fig. 4d) , and we did not detect any NAb responses to tier 2 viruses (data not shown). Thus, the mosaic Env immunogens elicited noninferior antibody responses as compared with the consensus or natural sequence Env antigens. Our data demonstrate that mosaic HIV-1 Gag, Pol and Env antigens augment both the breadth and depth of epitope-specific cellular immune responses as compared with consensus or natural sequence antigens in rhesus monkeys, in agreement with theoretical predictions (Supplementary Fig. 4) . In particular, a bivalent set of mosaic antigens proved superior to a bivalent set of clade B + clade C antigens, indicating that the augmented cellular immune breadth and depth was dependent on the mosaic antigen design 3, 12 , which not only maximized inclusion of common epitope variants but also excluded rare epitope variants that are unlikely to be useful in a vaccine. The results with the mosaic antigens in this study probably reflected the efficiency of rAd26 vectors in eliciting CD8 + T lymphocyte responses 5, 6 , together with the capacity of the mosaic antigens to augment CD8 + T lymphocyte breadth. The mosaic antigens also substantially enhanced CD4 + T lymphocyte breadth, but these effects were less marked and were characterized by lower total numbers of CD4 + T lymphocyte responses.
The importance of expanding cellular immune breadth has been demonstrated by recent studies showing that the breadth of Gagspecific T lymphocyte responses correlates with control of HIV-1 replication in chronically infected humans 4 and control of SIV replication after challenge of vaccinated rhesus monkeys 5 . In the phase 2b STEP study, the rAd5-based HIV-1 vaccine candidate expressing natural clade B Gag, Pol and Nef antigens elicited only a limited breadth of cellular immune responses, and no vaccine benefit was observed 13, 14 . This narrow breadth of cellular immune responses probably provided insufficient immunologic coverage of the diversity of infecting viruses. Moreover, viral escape from CD8 + T lymphocytes has been reported to occur during acute HIV-1 infection 15 , and cellular immune responses against variant epitopes have been shown to block SIV mutational evolution in rhesus monkeys in vivo 16 , thus suggesting a key role of expanding cellular immune depth. We were unable to assess the protective efficacy of mosaic HIV-1 vaccines in the present study as a result of the lack of an appropriate preclinical HIV-1 challenge model. Modeling the protective efficacy of mosaic vaccines against SIV challenges in nonhuman primates also has intrinsic limitations, as the observed diversity of SIV in natural hosts and HIV-1 in humans differs substantially and is influenced by different underlying biology 17, 18 .
In summary, this study shows that bivalent mosaic HIV-1 Gag, Pol and Env antigens expand cellular immune breadth and depth in rhesus monkeys as compared with consensus or natural sequence antigens. These findings have major implications for HIV-1 vaccine development, as global virus diversity and viral escape from cellular immune responses represent major hurdles in the development of a T cell-based HIV-1 vaccine. A bivalent cocktail of mosaic antigens is also practical and potentially feasible for clinical development. Moreover, the mosaic antigen strategy is generalizable and should be applicable for other genetically diverse pathogens in addition to HIV-1.
METHodS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
oNLINE METHodS
Antigen design. We constructed bivalent mosaic Gag, Pol and Env antigens to provide optimal coverage of HIV-1 M group sequences in the Los Alamos HIV-1 Sequence Database essentially as previously described 3, 19 , using the coverage of epitope length peptides in the global database as the selection criterion. We used the global sequence data set for each antigen, restricted to include only full-length proteins and one sequence per individual. We then fractured this set of proteins into all possible fragments of nine contiguous amino acids (nonamers). We tallied the nonamer frequencies and used a genetic algorithm to design and select in silico recombinant sequences that resembled real proteins and that maximized the number of nonamer sequence matches between the vaccine candidates and the global database. We selected the optimal clade C antigens with a similar selection strategy, but we used the clade C data set as the input sequences. We selected the single clade C Gag, Pol and Env natural sequences that provided optimal coverage of all nonamers in the global clade C data set (C.IN.-.70177 Gag, C.ZA.04.04ZASK208B1 Pol, C.SN.90.90SE_364 Env). The clade B antigens were previously selected to be near-consensus or consensus sequences with good coverage of the clade B data set (B.CAM-1 Gag, B.IIIB Pol, B.Con Env) 20 , and we used them to complement the optimal clade C antigens for the bivalent clade B + C vaccine approach. Pol antigens contained reverse transcriptase and integrase without protease and included point mutations to eliminate catalytic activity, as previously described 20 . Env gp140 antigens contained point mutations to eliminate cleavage and fusion activity. Vaccine sequences are depicted in Supplementary Figure 4 .
Vector production. We produced recombinant, replication-incompetent, E1/E3-deleted adenovirus serotype 26 (rAd26) and hexon-chimeric rAd-5HVR48 vectors expressing these antigens and purified them essentially as previously described 6, 10 . We expressed the HIV-1 antigens in the adenovirus E1 region under control of a human cytomegalovirus promoter.
Animals and immunizations.
We housed 27 outbred rhesus monkeys that did not express the major histocompatibility complex class I alleles 
